Clark et al. - Google Patents
c19) United States c12) Patent Application PublicationClark et al.
View PDF- Document ID
- 11730858053593315933
- Author
- Clark P
- Cho Y
- Umlauf B
External Links
Snippet
c19) United States c12) Patent Application Publication Page 1 1111111111111111 IIIIII IIIII
1111111111 11111 lllll lllll lllll lllll lllll 111111111111111 11111111 US 20200354472Al c19)
United States c12) Patent Application Publication Zorniak et al. c10) Pub. No.: US 2020/0354472 …
- 108090001123 antibodies 0 abstract description 277
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102037016B1 (en) | Anti PD-L1 Nano Antibody and Its Application | |
| JP6952827B2 (en) | Blood-brain barrier transport molecules and their use | |
| KR102014554B1 (en) | Fc receptor binding proteins | |
| JP6103801B2 (en) | Antibodies to T cells, immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof. | |
| EP2471814B1 (en) | Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody | |
| TW201946655A (en) | Novel antibody molecule, preparation method and use thereof | |
| US20240018263A1 (en) | Antibodies targeting glioblastoma stem-like cells and methods of use thereof | |
| US9096660B2 (en) | SPARC binding antibodies and uses thereof | |
| WO2019144677A1 (en) | Anti-ox40 antibody and use thereof | |
| WO2014194784A1 (en) | Human antibody against ed-b domain of fibronectin and uses thereof | |
| CN118240082A (en) | PD-1 binding molecules and their applications | |
| KR20220148699A (en) | Anti-CNTN4 specific antibody and its use | |
| CA3154072A1 (en) | Antigen-binding protein constructs and uses thereof | |
| EP4130041A1 (en) | Anti-pd-l1 and pd-l2 antibody and derivatives and use thereof | |
| CN115873114A (en) | CTLA-4 binding molecules and uses thereof | |
| US20250043015A1 (en) | Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof | |
| Clark et al. | c19) United States c12) Patent Application Publication | |
| JP6925274B2 (en) | Treatment | |
| Clark et al. | Zorniak et al. | |
| CN117836325A (en) | anti-TNFR 2 antibody and preparation method and application thereof | |
| CN108610422A (en) | Inhibit the binding molecule of PD-1/PD-L1 signal paths | |
| US20220348679A1 (en) | Antigen-binding protein constructs and uses thereof | |
| WO2025026358A1 (en) | Muc1 binding molecule and chimeric antigen receptor comprising same | |
| WO2024067759A1 (en) | Antibody capable of binding to cldn18.2 or antigen-binding fragment thereof and use thereof | |
| CN120230211A (en) | Anti-CDH17 antibody or antigen-binding fragment thereof and use thereof |